Low urine pH is associated with reduced indinavir crystalluria in indinavir-treated HIV-infected individuals.
Indinavir is a potent HIV-1 protease inhibitor included in current antiretroviral therapeutic regimens. It is associated with renal and urological complications ascribed to indinavir crystalluria. We have previously reported that indinavir crystalluria is frequently observed soon after initiation of therapy. In a cohort of 54 asymptomatic indinavir-naive HIV-1-infected individuals during their first year of treatment with indinavir, approximately 25% of urinalyses (U/A) contained indinavir crystals. Because the determinants of the crystalluria are unknown, we examined the relationship between urine specific gravity (SG) and pH, singly and in combination, and indinavir crystalluria in these subjects. A total of 579 U/A were obtained from the study subjects at their scheduled monthly outpatient medical assessments. The frequency of indinavir crystalluria was lower in U/A with lower pH, irrespective of the SG. Conversely, U/A with high pH (> or = 6.0) had a higher frequency of indinavir crystalluria, which was further influenced by the urine SG. As a result, nearly half of the U/A (46.7%) with high pH (> or = 6.0) and intermediate-high SG (> or = 1.015) contained indinavir crystals. In conclusion, the frequency of indinavir crystalluria in asymptomatic HIV-1 infected individuals during their first year of treatment with indinavir was markedly influenced by the urine pH and SG. Our findings suggest that low urine pH may have a protective effect against indinavir crystalluria across the entire range of urine SG.
Gagnon
R F
RF
Department of Medicine, McGill University Medical Center, Montreal, Qc, Canada. raymonde.gagnon@muhc.mcgill.ca
Alli
A I
AI
Edwardes
M D
MD
Watters
A K
AK
Tsoukas
C M
CM
D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use* / Q000652:urine*; D003460:Crystallization; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000652:urine*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D019469:Indinavir / Q000009:adverse effects / Q000627:therapeutic use* / Q000652:urine*; D008297:Male; D008875:Middle Aged; D013046:Specific Gravity; D016482:Urinalysis; D014556:Urine
D019380:Anti-HIV Agents; D019469:Indinavir